Savara (NASDAQ:SVRA) Posts Quarterly Earnings Results

Savara (NASDAQ:SVRA) released its quarterly earnings data on Tuesday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02), FiscalAI reports.

Savara Trading Down 2.8%

NASDAQ SVRA traded down $0.16 on Tuesday, hitting $5.57. 1,263,485 shares of the stock were exchanged, compared to its average volume of 1,620,952. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. The stock has a fifty day moving average price of $5.63 and a two-hundred day moving average price of $5.50. The firm has a market capitalization of $1.14 billion, a P/E ratio of -9.95 and a beta of 0.29. Savara has a 52-week low of $2.43 and a 52-week high of $7.01.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Oppenheimer started coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 price target for the company. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.14.

Institutional Investors Weigh In On Savara

Several hedge funds and other institutional investors have recently made changes to their positions in SVRA. VR Adviser LLC lifted its holdings in shares of Savara by 8.4% in the 4th quarter. VR Adviser LLC now owns 13,740,375 shares of the company’s stock worth $82,854,000 after acquiring an additional 1,059,332 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in Savara by 5.4% during the 3rd quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock valued at $31,328,000 after purchasing an additional 450,000 shares during the last quarter. RTW Investments LP bought a new position in Savara during the 4th quarter valued at about $35,893,000. Marshall Wace LLP purchased a new stake in Savara in the 4th quarter worth about $27,496,000. Finally, State Street Corp lifted its stake in Savara by 83.6% in the fourth quarter. State Street Corp now owns 4,333,022 shares of the company’s stock worth $26,128,000 after purchasing an additional 1,973,164 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.